108 related articles for article (PubMed ID: 21918510)
21. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.
Wiederkehr D; Berenson K; Casciano R; Stern L; Makenbaeva D; Mozaffari E; Lamerato L; Corbelli J
Curr Med Res Opin; 2009 Sep; 25(9):2317-25. PubMed ID: 19635042
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
25. Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).
Puymirat E; Aïssaoui N; Coste P; Dentan G; Bataille V; Drouet E; Mulak G; Carrié D; Blanchard D; Simon T; Danchin N
Am J Cardiol; 2011 Sep; 108(6):755-9. PubMed ID: 21726837
[TBL] [Abstract][Full Text] [Related]
26. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
[TBL] [Abstract][Full Text] [Related]
27. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.
Park KW; Park JJ; Kang J; Jeon KH; Kang SH; Han JK; Lee SE; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
PLoS One; 2013; 8(2):e52779. PubMed ID: 23418418
[TBL] [Abstract][Full Text] [Related]
28. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
L'Allier PL; Aronow HD; Cura FA; Bhatt DL; Albirini A; Schneider JP; Topol EJ; Ellis SG
Can J Cardiol; 2003 Aug; 19(9):1041-6. PubMed ID: 12915931
[TBL] [Abstract][Full Text] [Related]
29. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
[TBL] [Abstract][Full Text] [Related]
30. Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).
Koeth O; Zahn R; Gitt AK; Bauer T; Juenger C; Senges J; Zeymer U;
Am J Cardiol; 2009 Oct; 104(8):1074-7. PubMed ID: 19801027
[TBL] [Abstract][Full Text] [Related]
31. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Bonello L; De Labriolle A; Lemesle G; Steinberg DH; Roy P; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2009 Jun; 73(7):866-70. PubMed ID: 19198009
[TBL] [Abstract][Full Text] [Related]
32. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
Yang J; Zhou JS; Tan J; He BS; Zou JJ
Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
[TBL] [Abstract][Full Text] [Related]
33. The paraoxonase L55M and Q192R gene polymorphisms and myocardial infarction in a Tunisian population.
Kallel A; Sediri Y; Sbaï MH; Mourali MS; Feki M; Elasmi M; Taieb SH; Sanhaji H; Souheil O; Mechmeche R; Jemaa R; Kaabachi N
Clin Biochem; 2010 Dec; 43(18):1461-3. PubMed ID: 20833162
[TBL] [Abstract][Full Text] [Related]
34. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Martínez-Quintana E; Medina-Gil JM; Rodríguez-González F; Garay-Sánchez P; Limiñana JM; Saavedra P; Tugores A
J Clin Pharmacol; 2014 Aug; 54(8):843-9. PubMed ID: 24504666
[TBL] [Abstract][Full Text] [Related]
35. Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting.
Ma W; Liang Y; Zhu J; Chen T; Feng G; Yang Y; Liu X; Wang X
Atherosclerosis; 2016 Aug; 251():305-310. PubMed ID: 27450784
[TBL] [Abstract][Full Text] [Related]
36. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
Hochholzer W; Trenk D; Bestehorn HP; Fischer B; Valina CM; Ferenc M; Gick M; Caputo A; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2006 Nov; 48(9):1742-50. PubMed ID: 17084243
[TBL] [Abstract][Full Text] [Related]
37. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk.
Baum L; Ng HK; Woo KS; Tomlinson B; Rainer TH; Chen X; Cheung WS; Chan DK; Thomas GN; Tong CS; Wong KS
Clin Biochem; 2006 Mar; 39(3):191-5. PubMed ID: 16472799
[TBL] [Abstract][Full Text] [Related]
38. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.
Mehta RH; Roe MT; Mulgund J; Ohman EM; Cannon CP; Gibler WB; Pollack CV; Smith SC; Ferguson TB; Peterson ED
J Am Coll Cardiol; 2006 Jul; 48(2):281-6. PubMed ID: 16843176
[TBL] [Abstract][Full Text] [Related]
39. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women.
van Himbergen TM; van der Schouw YT; Voorbij HA; van Tits LJ; Stalenhoef AF; Peeters PH; Roest M
Atherosclerosis; 2008 Aug; 199(2):408-14. PubMed ID: 18164014
[TBL] [Abstract][Full Text] [Related]
40. Predicting clopidogrel response using DNA samples linked to an electronic health record.
Delaney JT; Ramirez AH; Bowton E; Pulley JM; Basford MA; Schildcrout JS; Shi Y; Zink R; Oetjens M; Xu H; Cleator JH; Jahangir E; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
Clin Pharmacol Ther; 2012 Feb; 91(2):257-63. PubMed ID: 22190063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
